Intuitive Q3 revenue rises 22% to $3.05bn as da Vinci placements jump to 546
Intuitive placed 546 da Vinci surgical robots in the third quarter of 2026, up from 427 a year earlier, and revenue rose 22% to $3.05 billion, the company said in its Oct 20 earnings release. A $450 million antitrust settlement cut GAAP profit to $523 million, and the full-year da Vinci procedure growth outlook now sits at 14% to 15%.
Intuitive placed 546 da Vinci surgical robots in the three months to Sept. 30, 28% more than a year earlier, and revenue rose 22% to $3.05 billion, the Sunnyvale, California company said in its third-quarter earnings release on Oct 20. Procedures on its da Vinci and Ion systems grew about 15%, with Ion bronchoscopy up about 31%.
The headline profit went the other way. GAAP net income fell to $523 million, or $1.49 a diluted share, from $704 million, because Intuitive booked a $450 million pre-tax charge to settle the antitrust class action known as In re: da Vinci Surgical Robot Antitrust Litigation. The question for investors is whether the settlement changes anything in a business that still grows revenue faster than procedures.
A quarter driven by robots, not only by instruments
Instruments and accessories, the per-procedure business, rose 18% to $1.80 billion and made up 59% of revenue. Systems revenue grew faster, by 30% to $769 million, and services rose 22% to $482 million. Of the 546 da Vinci placements, 315 were da Vinci 5, the newest platform, or 58% of the quarter against 56% a year ago. Ion placements rose to 56 from 50.
Leasing is now the default route into hospitals. Intuitive placed 291 systems under operating leases, 53% of the total, and 160 of them under usage-based leases, where the hospital pays as it operates. A year earlier usage-based deals were 115 of 427, or 27%; this quarter they were 29%.
- Total revenue
- 3,048.7
- 2,892.3
- 2,505.1
- Instruments and accessories
- 1,797.4
- 1,734.9
- 1,518.8
- Systems
- 769.1
- 685.0
- 590.4
- Services
- 482.2
- 472.4
- 395.9
- Gross profit
- 2,084.3
- 1,960.4
- 1,662.4
- Income from operations (GAAP)
- 592.6
- 971.9
- 759.7
- da Vinci placements (units)
- 546
- 468
- 427
Source: Intuitive earnings release, Oct 20, 2026 (Q2 placements from MEKAWIRE's Q2 report). Year-on-year revenue growth: 3,048.7 / 2,505.1 = 1.217, so 21.7%. Disclosed figures, not estimates.
As of Oct 20, 2026
The installed base grew to 12,094 da Vinci systems on Sept. 30 from 11,710 on June 30, as reported in Intuitive's second-quarter release. That is 384 net additions against 546 placements, which means about 162 systems left the base in the quarter, most likely as trade-ins for da Vinci 5. Intuitive does not break out trade-ins, so the number is our derivation, not a company figure.
What the $450 million buys
Intuitive said it reached a written agreement in October, after mediation in the da Vinci Surgical Robot Antitrust Litigation, to pay $450 million once and accept mutually agreed injunctive relief, without admitting liability. The release does not describe the injunctive terms. The settlement still needs preliminary and final court approval. Net of tax, the charge cost $347 million, or $0.99 a share. Without it, GAAP operating income would have been about $1.04 billion, above the $760 million of a year earlier.
The company also bought back 7.8 million shares for $2.94 billion, an average of about $377 a share, and cash and investments fell by $1.83 billion to $6.80 billion.
MEKAWIRE analysis
Intuitive is converting its installed base to da Vinci 5 through leases faster than challengers can place first robots, and the antitrust settlement is a one-off cost rather than a change to the instrument model, unless the undisclosed injunctive terms open the instrument market.
The outlook supports the first half of that view. In January Intuitive guided da Vinci procedure growth of 13% to 15%; it now guides 14% to 15% and says it expects to land near the midpoint. Non-GAAP gross margin guidance is 68.7% to 69.3%, including about 0.9% of revenue in tariff costs. GAAP gross margin this quarter was 68.4%, up from 66.4%.
The counter-argument is the settlement itself. The release does not say what the injunctive relief covers; if it lets third parties repair or reuse instruments, the 59% of revenue that comes from instruments faces price pressure for the first time. Medtronic, whose Hugo robot won US clearance in urology in December 2025, would gain from any opening.
Bull case: usage-based leasing keeps placements above 500 a quarter and lifts procedure share. Bear case: court-approved terms allow third-party instruments and margin guidance falls in 2027.
What to watch
- The court's preliminary approval filing and the text of the injunctive relief.
- Intuitive's 10-Q for the third quarter, which should give more detail on the settlement.
- The first 2027 outlook with fourth-quarter results in January 2027.
- 7.8m shares for $2.94bn in the quarter
- da Vinci procedure growth 14% to 15%, closer to the midpoint
- $3.00, vs $2.40
- 56, vs 50
- $523m, $1.49 per diluted share, after a $450m pre-tax antitrust settlement charge
- $3,048.7m, +22% from $2,505.1m
- 546 (315 da Vinci 5), vs 427 (240) in Q3 2025
- 12,094 da Vinci (+12%), 1,152 Ion (+21%)
Why it matters
Intuitive is the reference business for surgical robotics: 12,094 installed da Vinci systems and 546 placements in a quarter, more than most challengers have placed in total. Its leasing mix and its instrument revenue set the price and financing expectations that every new entrant, from Medtronic Hugo to CMR Surgical and Chinese makers, has to meet.
The quarter shows that da Vinci 5 upgrades and usage-based leases are doing the work. Systems revenue grew 30%, faster than procedures, which means hospitals are replacing older robots as well as adding new ones.
Rival analysis
Medtronic's Hugo is the only challenger with US clearance in a major specialty (urology, December 2025) backed by a medtech incumbent's sales force. CMR Surgical, Distalmotion and Moon Surgical do not publish quarterly placement counts comparable with Intuitive's 546. In China, MicroPort MedBot and Edge Medical compete in domestic tenders, a risk Intuitive itself names in its release.
The settlement matters more to rivals than to Intuitive's earnings. If injunctive relief eases restrictions on instruments or servicing, independent service and instrument suppliers gain an opening that challengers' own robots have not created.
Valuation context
Intuitive spent $2.94 billion on buybacks in the quarter at an average of about $377 a share (2,940 / 7.8), using its cash pile rather than debt. Cash and investments fell to $6.80 billion. Non-GAAP EPS rose 25% to $3.00, faster than revenue, because operating leverage and the buyback both helped.
GAAP figures carry the one-off $450 million charge; comparisons with peers should use operating income before the charge, about $1.04 billion.
Supply-chain implications
The release says Mexico makes a significant majority of Intuitive's instruments and accessories, Germany a majority of its endoscopes, and that certain materials are imported from China. The outlook carries a tariff cost of about 0.9% of revenue, and the quarter included a $22 million net benefit from refunds of tariffs paid under IEEPA in earlier periods.
Signals to watch
Court filings for preliminary approval of the $450 million settlement and the injunctive terms; the third-quarter 10-Q; da Vinci 5 share of placements (58% this quarter); the share of usage-based leases (29%); Intuitive's 2027 guidance in January 2027.
Analyst view
Thesis: the antitrust settlement is a one-off cost and the upgrade cycle continues. Confidence: medium, because the injunctive terms are not public. Our view would change if the approved relief allows third-party instrument reuse at scale or if quarterly placements fall below the 427 of a year ago.
Questions you should be asking
What are the injunctive terms and when do they take effect? How many of the 162 systems that left the base were trade-ins for da Vinci 5? Will usage-based leases keep rising as a share of placements, and what does that do to systems revenue per unit?